FDA Approval of Single Biomarker Blood Test

Elecsys Phospho-Tau 217P Plasma, jointly developed by Roche Holding AG and Eli Lilly and Company, received FDA approval on August 24, 2026. This test measures plasma phosphorylated tau 217 (pTau217) to detect brain amyloid pathology in adults aged 55 and older with cognitive decline symptoms or complaints. Its key differentiator is the use of a single biomarker and identical clinical cutoffs to support positive and negative determinations in both primary and specialty care settings.

Clinical Performance and Test Role

In clinical studies analyzing 2,148 individuals across five cohorts, the area under the curve (AUC) for distinguishing amyloid-positive and -negative cases was 0.878 in the cognitive impairment group and 0.907 in the cognitively normal group. A cutoff of less than 0.189 pg/mL is used to rule out amyloid pathology, achieving 98.98% sensitivity and 92.51% negative predictive value in the cognitive impairment group. Results are reported as positive, intermediate, or negative, but the test is not a standalone diagnostic tool. It enhances diagnostic pathway efficiency when combined with clinical judgment, amyloid PET, or cerebrospinal fluid testing.

Commercialization Foundation and Regulatory History

Elecsys pTau217 received European CE marking on May 12, 2026, and subsequently secured U.S. approval, entering the Marketed stage. It can be run on over 4,500 cobas instruments installed in the U.S., allowing healthcare facilities to expand testing without large-scale adoption of new analytical platforms. Labcorp and Quest Diagnostics plan to launch nationwide services in Q4 2026, potentially enabling faster test volume conversion compared to competitors relying on dedicated equipment.

Integration with Treatment Prescription Pathways

Confirming amyloid pathology is essential for patient selection for approved antibody therapies such as Lilly's Kisunla (donanemab-azbt) and Eisai·Biogen's Leqembi (lecanemab-irmb). Kisunla, an antibody targeting aggregated amyloid-beta plaques, received FDA approval on July 2, 2024, with an annual drug cost of approximately USD 32,000. By alleviating bottlenecks from PET and invasive lumbar puncture testing, low-cost blood screening could increase eligible patient enrollment and treatment initiation, creating strategic value for Lilly in both diagnostics and therapeutics.

Competitive Landscape and Market Implications

Direct competitors include Fujirebio Diagnostics' FDA-approved Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio and C2N Diagnostics' mass spectrometry-based PrecivityAD2. While Lumipulse uses a ratio of two biomarkers, Elecsys emphasizes its single pTau217 biomarker, broad cobas installation base, and primary care applicability. The U.S. Alzheimer's diagnostic market is projected to grow from USD 3.892 billion in 2025 to USD 8.766 billion in 2033, with the extent of blood biomarker adoption determining market share by displacing PET-centric revenue.